Depression - Pipeline Review, H2 2016

Publisher Name :
Date: 21-Sep-2016
No. of pages: 494
Inquire Before Buying
Avail Buy One-Get One Report Free on All GlobalMarketsDirect publisher Reports till 13 December 2019. To avail offer please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Markets Direct's, ‘Depression - Pipeline Review, H2 2016', provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Depression

  • The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Depression therapeutics and enlists all their major and minor projects

  • The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Depression

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Depression

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Avail Buy One-Get One Report Free on All GlobalMarketsDirect publisher Reports till 13 December 2019. To avail offer please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Depression - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
Introduction 8
Depression Overview 9
Therapeutics Development 10
Depression - Therapeutics under Development by Companies 12
Depression - Therapeutics under Investigation by Universities/Institutes 20
Depression - Pipeline Products Glance 22
Depression - Products under Development by Companies 26
Depression - Products under Investigation by Universities/Institutes 37
Depression - Companies Involved in Therapeutics Development 39
Depression - Therapeutics Assessment 131
Drug Profiles 151
Depression - Dormant Projects 432
Depression - Discontinued Products 457
Depression - Product Development Milestones 465
Appendix 474

List of Tables

Number of Products under Development for Depression, H2 2016 29
Number of Products under Development for Depression - Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 32
Number of Products under Development by Companies, H2 2016 (Contd..1) 33
Number of Products under Development by Companies, H2 2016 (Contd..2) 34
Number of Products under Development by Companies, H2 2016 (Contd..3) 35
Number of Products under Development by Companies, H2 2016 (Contd..4) 36
Number of Products under Development by Companies, H2 2016 (Contd..5) 37
Number of Products under Development by Companies, H2 2016 (Contd..6) 38
Number of Products under Investigation by Universities/Institutes, H2 2016 40
Comparative Analysis by Late Stage Development, H2 2016 41
Comparative Analysis by Clinical Stage Development, H2 2016 42
Comparative Analysis by Early Stage Development, H2 2016 43
Comparative Analysis by Unknown Stage Development, H2 2016 44
Products under Development by Companies, H2 2016 45
Products under Development by Companies, H2 2016 (Contd..1) 46
Products under Development by Companies, H2 2016 (Contd..2) 47
Products under Development by Companies, H2 2016 (Contd..3) 48
Products under Development by Companies, H2 2016 (Contd..4) 49
Products under Development by Companies, H2 2016 (Contd..5) 50
Products under Development by Companies, H2 2016 (Contd..6) 51
Products under Development by Companies, H2 2016 (Contd..7) 52
Products under Development by Companies, H2 2016 (Contd..8) 53
Products under Development by Companies, H2 2016 (Contd..9) 54
Products under Development by Companies, H2 2016 (Contd..10) 55
Products under Investigation by Universities/Institutes, H2 2016 56
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 57
Depression - Pipeline by AB Science SA, H2 2016 58
Depression - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 59
Depression - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 60
Depression - Pipeline by Adamed Sp. z o.o., H2 2016 61
Depression - Pipeline by Addex Therapeutics Ltd, H2 2016 62
Depression - Pipeline by Aequus Pharmaceuticals Inc., H2 2016 63
Depression - Pipeline by Alkermes Plc, H2 2016 64
Depression - Pipeline by Allergan Plc, H2 2016 65
Depression - Pipeline by Alvogen Korea Co., Ltd., H2 2016 66
Depression - Pipeline by Amorsa Therapeutics Inc., H2 2016 67
Depression - Pipeline by Anavex Life Sciences Corp., H2 2016 68
Depression - Pipeline by Angelini Group, H2 2016 69
Depression - Pipeline by Angita B.V., H2 2016 70
Depression - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 71
Depression - Pipeline by AstraZeneca Plc, H2 2016 72
Depression - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016 73
Depression - Pipeline by Axsome Therapeutics Inc, H2 2016 74
Depression - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 75
Depression - Pipeline by BioCrea GmbH, H2 2016 76
Depression - Pipeline by Biogen Inc, H2 2016 77
Depression - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016 78
Depression - Pipeline by BioLite, Inc., H2 2016 79
Depression - Pipeline by Bionomics Limited, H2 2016 80
Depression - Pipeline by Boehringer Ingelheim GmbH, H2 2016 81
Depression - Pipeline by Bristol-Myers Squibb Company, H2 2016 82
Depression - Pipeline by Calico LLC, H2 2016 83
Depression - Pipeline by Celon Pharma Sp. z o.o., H2 2016 84
Depression - Pipeline by Cerecor Inc., H2 2016 85
Depression - Pipeline by Clera Inc., H2 2016 86
Depression - Pipeline by D-Pharm Ltd., H2 2016 87
Depression - Pipeline by Delpor, Inc., H2 2016 88
Depression - Pipeline by e-Therapeutics Plc, H2 2016 89
Depression - Pipeline by Eisai Co., Ltd., H2 2016 90
Depression - Pipeline by Eli Lilly and Company, H2 2016 91
Depression - Pipeline by Evotec AG, H2 2016 92
Depression - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016 93
Depression - Pipeline by GlaxoSmithKline Plc, H2 2016 94
Depression - Pipeline by GliaCure Inc., H2 2016 95
Depression - Pipeline by H. Lundbeck A/S, H2 2016 96
Depression - Pipeline by Heptares Therapeutics Limited, H2 2016 97
Depression - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 98
Depression - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 99
Depression - Pipeline by Impel NeuroPharma, Inc., H2 2016 100
Depression - Pipeline by INSYS Therapeutics, Inc., H2 2016 101
Depression - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 102
Depression - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 103
Depression - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 104
Depression - Pipeline by Johnson & Johnson, H2 2016 105
Depression - Pipeline by KemPharm, Inc., H2 2016 106
Depression - Pipeline by Lead Discovery Center GmbH, H2 2016 107
Depression - Pipeline by Les Laboratoires Servier SAS, H2 2016 108
Depression - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 109
Depression - Pipeline by Luye Pharma Group Ltd., H2 2016 110
Depression - Pipeline by Mapi Pharma Ltd., H2 2016 111
Depression - Pipeline by Mapreg S.A.S., H2 2016 112
Depression - Pipeline by Meta-IQ ApS, H2 2016 113
Depression - Pipeline by Methylation Sciences Inc., H2 2016 114
Depression - Pipeline by miCure Therapeutics Ltd., H2 2016 115
Depression - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 116
Depression - Pipeline by Navya Biologicals Pvt Ltd, H2 2016 117
Depression - Pipeline by Neuralstem, Inc., H2 2016 118
Depression - Pipeline by Neurocrine Biosciences, Inc., H2 2016 119
Depression - Pipeline by NeuroNascent, Inc., H2 2016 120
Depression - Pipeline by NeurOp, Inc, H2 2016 121
Depression - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016 122
Depression - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 123
Depression - Pipeline by nLife Therapeutics, S.L., H2 2016 124
Depression - Pipeline by Novartis AG, H2 2016 125
Depression - Pipeline by Omeros Corporation, H2 2016 126
Depression - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 127
Depression - Pipeline by Pfizer Inc., H2 2016 128
Depression - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016 129
Depression - Pipeline by Polleo Pharma Limited, H2 2016 130
Depression - Pipeline by Protagenic Therapeutics Inc., H2 2016 131
Depression - Pipeline by Relmada Therapeutics, Inc., H2 2016 132
Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 133
Depression - Pipeline by Richter Gedeon Nyrt., H2 2016 134
Depression - Pipeline by Saniona AB, H2 2016 135
Depression - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 136
Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 137
Depression - Pipeline by Supernus Pharmaceuticals, Inc., H2 2016 138
Depression - Pipeline by Suven Life Sciences Ltd., H2 2016 139
Depression - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 140
Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 141
Depression - Pipeline by Tetra Discovery Partners LLC, H2 2016 142
Depression - Pipeline by Trevena, Inc., H2 2016 143
Depression - Pipeline by TRImaran Pharma, Inc., H2 2016 144
Depression - Pipeline by Turing Pharmaceuticals AG , H2 2016 145
Depression - Pipeline by VistaGen Therapeutics , Inc., H2 2016 146
Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H2 2016 147
Depression - Pipeline by Zogenix, Inc., H2 2016 148
Depression - Pipeline by Zysis Limited, H2 2016 149
Assessment by Monotherapy Products, H2 2016 150
Assessment by Combination Products, H2 2016 151
Number of Products by Stage and Target, H2 2016 153
Number of Products by Stage and Mechanism of Action, H2 2016 160
Number of Products by Stage and Route of Administration, H2 2016 167
Number of Products by Stage and Molecule Type, H2 2016 169
Depression - Dormant Projects, H2 2016 451
Depression - Dormant Projects (Contd..1), H2 2016 452
Depression - Dormant Projects (Contd..2), H2 2016 453
Depression - Dormant Projects (Contd..3), H2 2016 454
Depression - Dormant Projects (Contd..4), H2 2016 455
Depression - Dormant Projects (Contd..5), H2 2016 456
Depression - Dormant Projects (Contd..6), H2 2016 457
Depression - Dormant Projects (Contd..7), H2 2016 458
Depression - Dormant Projects (Contd..8), H2 2016 459
Depression - Dormant Projects (Contd..9), H2 2016 460
Depression - Dormant Projects (Contd..10), H2 2016 461
Depression - Dormant Projects (Contd..11), H2 2016 462
Depression - Dormant Projects (Contd..12), H2 2016 463
Depression - Dormant Projects (Contd..13), H2 2016 464
Depression - Dormant Projects (Contd..14), H2 2016 465
Depression - Dormant Projects (Contd..15), H2 2016 466
Depression - Dormant Projects (Contd..16), H2 2016 467
Depression - Dormant Projects (Contd..17), H2 2016 468
Depression - Dormant Projects (Contd..18), H2 2016 469
Depression - Dormant Projects (Contd..19), H2 2016 470
Depression - Dormant Projects (Contd..20), H2 2016 471
Depression - Dormant Projects (Contd..21), H2 2016 472
Depression - Dormant Projects (Contd..22), H2 2016 473
Depression - Dormant Projects (Contd..23), H2 2016 474
Depression - Dormant Projects (Contd..24), H2 2016 475
Depression - Discontinued Products, H2 2016 476
Depression - Discontinued Products (Contd..1), H2 2016 477
Depression - Discontinued Products (Contd..2), H2 2016 478
Depression - Discontinued Products (Contd..3), H2 2016 479
Depression - Discontinued Products (Contd..4), H2 2016 480
Depression - Discontinued Products (Contd..5), H2 2016 481
Depression - Discontinued Products (Contd..6), H2 2016 482
Depression - Discontinued Products (Contd..7), H2 2016 483

List of Figures

Number of Products under Development for Depression, H2 2016 29
Number of Products under Development for Depression - Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
Number of Products under Investigation by Universities/Institutes, H2 2016 39
Comparative Analysis by Late Stage Development, H2 2016 41
Comparative Analysis by Clinical Stage Development, H2 2016 42
Comparative Analysis by Early Stage Products, H2 2016 43
Assessment by Monotherapy Products, H2 2016 150
Assessment by Combination Products, H2 2016 151
Number of Products by Top 10 Targets, H2 2016 152
Number of Products by Stage and Top 10 Targets, H2 2016 152
Number of Products by Top 10 Mechanism of Actions, H2 2016 159
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 159
Number of Products by Top 10 Routes of Administration, H2 2016 166
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 166
Number of Products by Top 10 Molecule Types, H2 2016 168
Number of Products by Stage and Top 10 Molecule Types, H2 2016 168
  • Global Alcohol Addiction Therapeutics Market Professional Survey Report 2019
    Published: 03-Dec-2019        Price: US 3500 Onwards        Pages: 119
    The global Alcohol Addiction Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Alcohol Addiction Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Alcohol Addiction Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes ......
  • Global Gabapentin Market Research (2015-2019) and Future Forecast (2020-2025)
    Published: 22-Nov-2019        Price: US 3300 Onwards        Pages: 116
    Summary Gabapentin is an anti-epileptic medication, also called an anticonvulsant. It affects chemicals and nerves in the body that are involved in the cause of seizures and some types of pain. The report forecast global Gabapentin market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025. The report offers detailed coverage of Gabapentin industry and main market trends. The market research includes historical and ......
  • Global Gabapentin Market Study 2016-2026, by Segment (Tablet, Capsule) , by Market (Nerve Pain, Restless Legs Syndrome,) , by Company (Pfizer, GSK,)
    Published: 13-Nov-2019        Price: US 1800 Onwards        Pages: 49
    Summary Gabapentin is an anti-epileptic medication, also called an anticonvulsant. It affects chemicals and nerves in the body that are involved in the cause of seizures and some types of pain. The global Gabapentin market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026. Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.): - Tablet - Capsule Demand Coverage (Marke......
  • Alcohol Addiction - Pipeline Review, H2 2019
    Published: 11-Nov-2019        Price: US 2000 Onwards        Pages: 174
    Alcohol Addiction - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Pipeline Review, H2 2019, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape. Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability t......
  • Global Epilepsy Therapeutics Market Professional Survey Report 2019
    Published: 05-Nov-2019        Price: US 3500 Onwards        Pages: 108
    The global Epilepsy Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Epilepsy Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Epilepsy Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent co......
  • Global Autism Spectrum Disorder Market Growth (Status and Outlook) 2019-2024
    Published: 30-Oct-2019        Price: US 3660 Onwards        Pages: 115
    According to this study, over the next five years the Autism Spectrum Disorder market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Autism Spectrum Disorder business, shared in Chapter 3. This report presents a comprehensive overview, market shares and growth opportunities of Autism Spectrum Disorder market b......
  • Global Gabapentin Market Growth 2019-2024
    Published: 24-Oct-2019        Price: US 3660 Onwards        Pages: 159
    According to this study, over the next five years the Gabapentin market will register a 1.9% CAGR in terms of revenue, the global market size will reach US$ 1537.4 million by 2024, from US$ 1426 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Gabapentin business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Gabapentin market by product type, applic......
  • Global Biopolar Disorder Therapeutics Market Professional Survey Report 2019
    Published: 26-Sep-2019        Price: US 3500 Onwards        Pages: 107
    Bipolar disorder, also known as manic depression, is a mental disorder that could lead to periods of depression and elevated mood. The treatment of bipolar disorder includes psychotherapy as well as medications such as mood stabilizers and antipsychotics. Rise in prevalence of bipolar disorder, high unmet medical needs, technological advancement and government initiatives are the key factors accelerating the growth of the bipolar disorder therapeutics market. Increase in investment in res......
  • Global Neurodegenerative Diseases Market Professional Survey Report 2019
    Published: 12-Sep-2019        Price: US 3500 Onwards        Pages: 114
    Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages. ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs